Nifty
:
16945.05
Sensex
:
57527.10
-131.85 (-0.77%)
-398.18 (-0.69%)
Nifty
Sensex
:
:
16945.05
57527.10
-131.85 (-0.77%)
-398.18 (-0.69%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
972.85
24-Mar-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 977.60
  • 979.00
  • 968.00
  • 977.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1534322
  •  14942.88
  •  1072.15
  •  789.90

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 233,407.31
  • 55.42
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 229,664.26
  • 1.03%
  • 4.22

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.31%
  • 5.76%
  • FII
  • DII
  • Others
  • 16.87%
  • 18.07%
  • 2.51%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.09
  • 7.91
  • 5.59

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.35
  • 12.29
  • 7.22

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.96
  • 9.17
  • -4.53

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 41.03
  • 41.90
  • 56.25

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.13
  • 3.31
  • 3.66

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.98
  • 17.10
  • 18.06

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Net Sales
11,240.97
9,863.06
13.97%
10,952.28
9,625.93
13.78%
10,761.76
9,718.74
10.73%
9,446.76
8,522.98
10.84%
Expenses
8,237.25
7,256.73
13.51%
7,995.73
6,995.99
14.29%
8,023.04
6,977.54
14.98%
7,267.41
6,474.54
12.25%
EBITDA
3,003.72
2,606.33
15.25%
2,956.55
2,629.94
12.42%
2,738.72
2,741.20
-0.09%
2,179.35
2,048.44
6.39%
EBIDTM
26.72%
26.43%
26.99%
27.32%
25.45%
28.21%
23.07%
24.03%
Other Income
173.88
432.51
-59.80%
85.22
222.89
-61.77%
147.81
232.40
-36.40%
274.61
111.00
147.40%
Interest
46.18
18.97
143.44%
19.39
35.95
-46.06%
13.69
35.09
-60.99%
37.34
30.10
24.05%
Depreciation
659.95
553.68
19.19%
609.95
530.37
15.00%
588.00
503.22
16.85%
556.47
553.49
0.54%
PBT
2,471.47
2,466.19
0.21%
2,412.43
2,286.51
5.51%
2,284.84
1,804.22
26.64%
-2,075.60
903.04
-
Tax
283.43
335.39
-15.49%
152.26
197.78
-23.02%
188.99
395.57
-52.22%
146.76
55.04
166.64%
PAT
2,188.04
2,130.80
2.69%
2,260.17
2,088.73
8.21%
2,095.85
1,408.65
48.78%
-2,222.36
848.00
-
PATM
19.46%
21.60%
20.64%
21.70%
19.48%
14.49%
-23.53%
9.95%
EPS
9.03
8.58
5.24%
9.43
8.53
10.55%
8.59
6.02
42.69%
-9.49
3.73
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
42,401.77
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
Net Sales Growth
12.38%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
42.31%
 
Cost Of Goods Sold
10,951.57
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
Gross Profit
31,450.20
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
GP Margin
74.17%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
81.62%
Total Expenditure
31,523.43
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
Power & Fuel Cost
-
667.52
627.09
621.89
613.60
559.97
525.09
545.44
560.77
232.41
187.10
% Of Sales
-
1.73%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
Employee Cost
-
6,565.27
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
% Of Sales
-
16.98%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
Manufacturing Exp.
-
3,514.38
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
618.43
% Of Sales
-
9.09%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
5.47%
General & Admin Exp.
-
2,449.91
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
793.38
% Of Sales
-
6.34%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
7.02%
Selling & Distn. Exp.
-
4,075.02
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
% Of Sales
-
10.54%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
Miscellaneous Exp.
-
1,149.04
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
847.67
763.01
% Of Sales
-
2.97%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
4.11%
EBITDA
10,878.34
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
EBITDA Margin
25.66%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
Other Income
681.52
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
422.23
Interest
116.60
127.35
141.43
302.73
555.25
517.57
399.80
523.24
578.99
44.19
43.16
Depreciation
2,414.37
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
PBT
5,093.14
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
Tax
771.44
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
845.55
Tax Rate
15.15%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
19.57%
PAT
4,321.70
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
PAT before Minority Interest
4,230.90
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
Minority Interest
-90.80
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
PAT Margin
10.19%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
26.46%
PAT Growth
-33.27%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
5.08%
 
EPS
18.01
13.71
12.15
15.75
11.12
8.84
28.99
18.94
18.97
13.09
12.46

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
240.66
207.12
207.12
103.56
Total Reserves
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
Non-Current Liabilities
-1,363.51
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
199.02
Secured Loans
251.79
7.83
6.18
109.47
217.69
185.59
7.73
40.69
43.76
41.90
Unsecured Loans
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
Long Term Provisions
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
Current Liabilities
17,200.55
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
Trade Payables
4,479.34
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
Other Current Liabilities
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
Short Term Borrowings
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
Short Term Provisions
9,325.96
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
Total Liabilities
66,903.15
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
Net Block
22,459.74
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
Gross Block
38,501.94
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
Accumulated Depreciation
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
Non Current Assets
31,888.17
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
Capital Work in Progress
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
Non Current Investment
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
Long Term Loans & Adv.
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
802.56
Other Non Current Assets
46.12
4.67
5.53
21.96
50.21
682.18
953.34
103.94
34.20
42.90
Current Assets
35,014.98
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
Current Investments
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
Inventories
8,996.81
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
Sundry Debtors
10,592.89
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
Cash & Bank
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
Other Current Assets
2,757.99
1,319.11
1,541.48
1,266.30
2,919.93
3,546.51
2,847.64
5,026.16
3,774.42
1,149.11
Short Term Loans & Adv.
1,692.55
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
Net Current Assets
17,814.43
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
Total Assets
66,903.15
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
PBT
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
Adjustment
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
Changes in Working Capital
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
-44.83
Cash after chg. in Working capital
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
Net Fixed Assets
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
Net Investments
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
Others
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
Cash from Financing Activity
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
Net Cash Inflow / Outflow
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
Opening Cash & Equivalents
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
Closing Cash & Equivalent
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
200.11
193.65
188.66
172.59
159.69
152.70
137.03
123.49
89.44
72.37
ROA
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
16.21%
19.61%
ROE
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
23.15%
25.53%
ROCE
9.25%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
25.46%
31.39%
Fixed Asset Turnover
1.81
1.74
1.78
1.92
1.99
1.29
1.34
1.79
1.70
1.51
Receivable days
53.38
54.88
56.22
54.10
53.53
83.25
76.12
48.20
51.72
71.46
Inventory Days
48.87
50.10
48.40
47.84
48.88
78.98
77.46
57.99
63.92
74.22
Payable days
149.03
158.71
152.86
77.81
90.19
85.47
75.24
52.05
56.33
65.15
Cash Conversion Cycle
-46.77
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
59.31
80.53
Total Debt/Equity
0.03
0.08
0.18
0.25
0.27
0.27
0.26
0.35
0.14
0.02
Interest Cover
36.19
20.79
17.55
7.86
7.72
23.63
13.56
12.06
104.67
101.13

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Sun Pharmaceutical Industries completes acquisition of Concert Pharmaceuticals
    8th Mar 2023, 11:59 AM

    This acquisition is an opportunity to bring deuruxolitinib to market globally and make a meaningful difference to alopecia areata patients around the world

    Read More
  • Sun Pharmaceutical Industries to acquire stakes in Agatsa Software, Remidio Innovative Solutions
    20th Feb 2023, 10:30 AM

    The company has entered into agreements to acquire minority stake in Agatsa Software and Remidio Innovative Solutions which are non-material investments by the Company in the allied areas

    Read More
  • Sun Pharma’s arm recalling over 34,000 bottles of generic medication in US
    13th Feb 2023, 11:28 AM

    The company initiated the Class II nationwide recall (US) on January 13 this year

    Read More
  • Sun Pharma’s arm receives USFDA’s approval for Generic Lenalidomide Capsules
    10th Feb 2023, 12:12 PM

    The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product

    Read More
  • Sun Pharmaceutical Industries reports marginal rise in Q3 consolidated net profit
    31st Jan 2023, 15:20 PM

    Total consolidated income of the company increased by 10.87% to Rs 11,414.85 crore for Q3FY23

    Read More
  • Sun Pharma Inds. - Quarterly Results
    31st Jan 2023, 13:28 PM

    Read More
  • Sun Pharma acquires three anti-inflammatory brands from Aksigen Hospital Care
    30th Jan 2023, 14:30 PM

    The company has acquired Disperzyme, Disperzyme-CD and Phlogam as part of the deal

    Read More
  • Sun Pharmaceutical Industries launches SEZABY in U.S.
    25th Jan 2023, 15:17 PM

    SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection

    Read More
  • Sun Pharma to acquire Concert Pharmaceuticals
    20th Jan 2023, 10:08 AM

    Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry

    Read More
  • USFDA pulls up Sun Pharma for manufacturing lapses in Halol plant
    14th Jan 2023, 15:41 PM

    The health regulator inspected the manufacturing facility from April 26 to May 9, 2022

    Read More
  • Sun Pharmaceutical Industries launches Palbociclib in India
    11th Jan 2023, 12:14 PM

    The company will make the drug available under the brand name, PALENO (Palbociclib) 75 mg, 100 mg, 125 mg

    Read More
  • Sun Pharma receives warning letter from USFDA for Halol facility
    17th Dec 2022, 16:13 PM

    The Warning Letter summarizes violations with respect to Current Good Manufacturing Practice regulations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.